Top

Published in:

01-10-2012 | Original article

Hodgkin’s lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses

Authors: Carolin Winkler, Daniel Sebastian Steingrube, Wolfgang Altermann, Gerald Schlaf, Daniela Max, Stefanie Kewitz, Alexander Emmer, Malte Kornhuber, Ursula Banning-Eichenseer, Martin Sebastian Staege

Published in: Cancer Immunology, Immunotherapy | Issue 10/2012

Abstract

Cytotoxic T lymphocytes (CTL) can kill Hodgkin’s lymphoma (HL) cells, and CTL have been used for the treatment of Epstein-Barr virus (EBV)-positive HL. For patients with EBV-negative HL, this strategy cannot be employed and alternative target structures have to be defined. In order to establish a system for the stimulation of HL-reactive T cells, we used dendritic cells (DC) as antigen-presenting cells for autologous T cells and transfected these DC with RNA from established HL cell lines. After stimulation of peripheral blood mononuclear cells (PBMC) with RNA-transfected DC, we analyzed the reactivity of primed PBMC by interferon gamma enzyme-linked immunospot. Our results suggest the presence of antigens with expression in HL cell lines and recognition of these antigens in combination with DC-derived human leukocyte antigen molecules. By the analysis of Gene Expression Omnibus microarray data sets from HL cell lines and primary HL samples in comparison with testis and other normal tissues, we identified HL-associated cancer testis antigens (CTA) including the preferentially expressed antigen in melanoma (PRAME). After stimulation of PBMC with RNA-transfected DC, we detected PRAME-reactive T cells. PRAME and other HL-associated CTA might be targets for HL-specific immune therapy or for the monitoring of HL-directed immune responses.

Available only for authorised users

Drexler HG, Minowada J (1992) Hodgkin’s disease derived cell lines: a review. Hum Cell 5:42–53PubMed

Sahin U, Neumann F, Tureci O, Schmits R, Perez F, Pfreundschuh M (2002) Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells. Blood 100:4139–4145PubMedCrossRef

Schwering I, Bräuninger A, Klein U, Jungnickel B, Tinguely M, Diehl V et al (2003) Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101:1505–1512PubMedCrossRef

Körholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F et al (2004) The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin’s disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 216:150–156PubMedCrossRef

Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al (2005) Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365:1934–1941PubMedCrossRef

Kennedy-Nasser AA, Bollard CM, Rooney CM (2006) Adoptive immunotherapy for Hodgkin’s lymphoma. Int J Hematol 83:385–390PubMedCrossRef

Grunebach F, Muller MR, Brossart P (2005) New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol Immunother 54:517–525PubMedCrossRef

Staege MS, Hansen G, Baersch G, Burdach S (2004) Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy. Pediatr Blood Cancer 43:23–34PubMedCrossRef

Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A et al (2010) Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther 21:285–297PubMedCrossRef

10.

Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M et al (2005) Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 93:749–756PubMedCrossRef

11.

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S et al (2007) T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 56:659–675PubMedCrossRef

12.

Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, Richter G et al (2008) Gene expression profiles of Hodgkin’s lymphoma cell lines with different sensitivity to cytotoxic drugs. Exp Hematol 36:886–896PubMedCrossRef

13.

Biedler JL, Helson L, Spengler BA (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33:2643–2652PubMed

14.

McAllister RM, Isaacs H, Rongey R, Peer M, Au W, Soukup SW et al (1977) Establishment of a human medulloblastoma cell line. Int J Cancer 20:206–212PubMedCrossRef

15.

Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B et al (1996) Peripheral blood mononuclear cells of a patient with advanced Hodgkin’s lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 87:3418–3428PubMed

16.

Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, Gerdes J et al (1981) Hodgkin’s disease: establishment and characterization of four in vitro cell lines. J Cancer Res Clin Oncol 101:111–124PubMedCrossRef

17.

Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J (1986) Hodgkin’s disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res 10:487–500PubMedCrossRef

18.

Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H et al (1986) Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin’s disease. Blood 68:285–292PubMed

19.

Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H et al (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51:1417–1423PubMed

20.

Salcedo M, Momburg F, Hämmerling GJ, Ljunggren HG (1994) Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells. J Immunol 152:1702–1708PubMed

21.

Foell JL, Volkmer I, Giersberg C, Kornhuber M, Horneff G, Staege MS (2008) Loss of detectability of Charcot-Leyden crystal protein transcripts in blood cells after treatment with dimethyl sulfoxide. J Immunol Methods 339:99–103PubMedCrossRef

22.

Meyer-Wentrup F, Burdach S (2003) Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations. J Hematother Stem Cell Res 12:289–299PubMedCrossRef

23.

Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS (2008) Membrane-associated phospholipase A1 beta (LIPI) is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 51:228–234PubMedCrossRef

24.

Neumann I, Foell JL, Bremer M, Volkmer I, Korholz D, Burdach S et al (2010) Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate. Pediatr Blood Cancer 55:464–470PubMedCrossRef

25.

Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W et al (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402PubMedCrossRef

26.

Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM et al (2005) Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 86:127–141PubMedCrossRef

27.

Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF et al. (2011) NCBI GEO: archive for functional genomics data sets–10 years on. Nucleic Acids Res 39 Database issue:D1005-1010

28.

Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18:207–208PubMedCrossRef

29.

Dangond F, Hwang D, Camelo S, Pasinelli P, Frosch MP, Stephanopoulos G et al (2004) Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol Genomics 16:229–239PubMed

30.

Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ et al (2008) Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 205:2251–2268PubMedCrossRef

31.

Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC et al (2006) Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 7:67–80PubMedCrossRef

32.

Eckerle S, Brune V, Döring C, Tiacci E, Bohle V, Sundström C et al (2009) Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 23:2129–2138PubMedCrossRef

33.

Köchert K, Ullrich K, Kreher S, Aster JC, Kitagawa M, Jöhrens K et al (2010) High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas. Oncogene 30:1831–1840PubMedCrossRef

34.

Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P et al (2011) MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471:377–381PubMedCrossRef

35.

Liu TY, Wu SJ, Huang MH, Lo FY, Tsai MH, Tsai CH et al (2010) EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Mol Cancer 9:32PubMedCrossRef

36.

Hoennscheidt C, Max D, Richter N, Staege MS (2009) Expression of CD4 on Epstein-Barr virus-immortalized B cells. Scand J Immunol 70:216–225PubMedCrossRef

37.

Ghafouri-Fard S, Abbasi A, Moslehi H, Faramarzi N, Taba Taba Vakili S, Mobasheri MB et al (2010) Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features. Br J Dermatol 162:772–779PubMedCrossRef

38.

Chen YT, Chadburn A, Lee P, Hsu M, Ritter E, Chiu A et al (2010) Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci USA 107:3093–3098PubMedCrossRef

39.

Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E et al (2006) Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin’s lymphoma. Haematologica 91:596–604PubMed

40.

Thorisson GA, Smith AV, Krishnan L, Stein LD (2005) The international HapMap project Web site. Genome Res 15:1592–1593PubMedCrossRef

41.

Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208PubMedCrossRef

42.

Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM et al (2001) Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193:73–88PubMedCrossRef

43.

Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S et al (2011) High-avidity cytotoxic-T-lymphocytes specific for a new preferentially expressed antigen of melanoma (PRAME)-derived peptide can target leukemic- and leukemic-precursor cells. Blood 117:3353–3362PubMedCrossRef

44.

Kawahara M, Hori T, Matsubara Y, Okawa K, Uchiyama T (2006) Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis. Exp Hematol 34:1496–1504PubMedCrossRef

45.

Parmiani G, De Filippo A, Novellino L, Castelli C (2007) Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178:1975–1979PubMed

46.

Gao L, Downs AM, Stauss HJ (2005) Immunotherapy with CTL restricted by nonself MHC. Methods Mol Med 109:215–228PubMed

47.

Lin W, Lai CH, Tang CJ, Huang CJ, Tang TK (1999) Identification and gene structure of a novel human PLZF-related transcription factor gene, TZFP. Biochem Biophys Res Commun 264:789–795PubMedCrossRef

48.

Kaufmann S, Sauter M, Schmitt M, Baumert B, Best B, Boese A et al (2010) Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor. J Gen Virol 91:1494–1502PubMedCrossRef

49.

Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D et al (2010) Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 16:571–579PubMedCrossRef

50.

Khong HT, Wang QJ, Rosenberg SA (2004) Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 27:184–190PubMedCrossRef

51.

Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T et al (2009) The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114:3299–3308PubMedCrossRef

52.

Ortmann CA, Eisele L, Nückel H, Klein-Hitpass L, Führer A, Dührsen U et al (2008) Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol 87:809–818PubMedCrossRef

53.

Morandi F, Chiesa S, Bocca P, Millo E, Salis A, Solari M et al (2006) Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 8:833–842PubMedCrossRef

Title: Hodgkin’s lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses
Authors: Carolin Winkler
Daniel Sebastian Steingrube
Wolfgang Altermann
Gerald Schlaf
Daniela Max
Stefanie Kewitz
Alexander Emmer
Malte Kornhuber
Ursula Banning-Eichenseer
Martin Sebastian Staege
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 10/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-012-1239-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2012

Inhibition of stromal CXCR4 impairs development of lung metastases

Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

In memory of Professor Robert W. Baldwin: Editor-in-Chief of Cancer Immunology, Immunotherapy 1976–2003

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation

Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer